Leucine‐rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule‐associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

Abstract Mutations in LRRK2 (encoding leucine‐rich repeat kinase 2 protein, LRRK2) are the most common genetic risk factors for Parkinson's disease (PD), and increased LRRK2 kinase activity was observed in sporadic PD. Therefore, inhibition of LRRK2 has been tested as a disease‐modifying therapeutic...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Kang Chen, Fei Tang, Bin Du, Zhe‐Zhou Yue, Ling‐Ling Jiao, Xu‐Long Ding, Qing‐Zhang Tuo, Jie Meng, Si‐Yu He, Lunzhi Dai, Peng Lei, Xia‐Wei Wei
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Wiley 2023-12-01
Rangatū:	MedComm
Ngā marau:	A53T LRRK2 MAP1B MPTP Parkinson's disease
Urunga tuihono:	https://doi.org/10.1002/mco2.429
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!